ONC Utang marang Ekuitas beigene.com

Logo korporat perusahaan BeiGene Oncology (ONC)

R&D complexity and stringent FDA oversight create colossal barriers to entry for the sector. The history of total debt-to-equity changes on the GURU.Markets chart demonstrates leverage dynamics, where the current level is approximately 0.38. BeiGene Ltd (ONC) strengthens physician confidence through its status as a global innovator, although geopolitical pressure and expansion costs create certain risks.

ONC: Rasio Total Utang marang Ekuitas beigene.com 04.07.2022 - 30.10.2026
Barang utama beigene.com

Analyzing the capital structure allows for the separation of fundamental business stability from market price volatility. This metric measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage. The trend in the total financial debt-to-equity ratio demonstrates the company's dependence on external creditors. For BeiGene Ltd (ONC), low leverage mitigates the risks of geopolitical pressure on the biotechnology sector. This provides a financial reserve for the costly expansion of oncology drugs.

Analisis perusahaan pesaing

HALO (Halozyme) - Total Utang marang Modal|Total Utang marang Modal Revolution Medicines Inc|Utang marang Ekuitas Ascentage (AAPG)|CG Oncology Therapeutics - Rasio Utang marang Ekuitas|Total Utang marang Modal URGN (UroGen Pharma Ltd.)|BCAX - Rasio Total Utang marang Ekuitas|Personalis - Total Utang marang Modal|Utang marang Modal Erasca Inc|Delcath (DCTH) - Utang marang Ekuitas|Y-mAbs Corp - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas AURA|CADL: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ARAY|Rasio Total Utang marang Ekuitas sellaslifesciences.com SLS|Actuate Therapeutics, Inc - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Citius Oncology Inc CTOR|HURA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi TARA (protaratx.com)|FATE: Total Utang marang Modal|Utang marang Modal Aadi Bioscience (WHWK)|TCRX (TScan Therapeutics Inc) - Total Utang marang Modal|Utang marang Ekuitas CSBR|Total Utang marang Modal XBIT|CVM - Utang marang Modal|Total Utang marang Modal OSTX (OS Therapies)|Koefisien Total Utang marang Modal radiopharmtheranostics.com (RADX)|Artiva - Total Utang marang Modal|Rasio Utang marang Modal Adlai Nortye Ltd. (ANL)|VERU: Total Utang marang Modal|Utang marang Modal tempesttx.com (TPST)|Utang marang Ekuitas Xilio Therapeutics Inc|Rasio Utang marang Ekuitas RENB (Enochian BioSciences)|Total Utang marang Modal MURA|KAPA - Utang marang Modal|OnKure Therapeutics - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GDTC|CRIS - Utang marang Ekuitas|APLM: Utang marang Ekuitas|THAR (Tharimmune Corp) - Rasio Total Utang marang Ekuitas|ADVB: Utang Agregat marang Modal|GNPX (Genprex, Inc.) - Total Utang marang Modal|Rasio Utang marang Ekuitas CLDI (Calidi Bio)|Utang marang Ekuitas Sunshine Biopharma, Inc. (SBFM)|XBIO - Utang marang Modal|Utang marang Ekuitas Salarius SLRX|PPBT: Rasio Utang marang Ekuitas|AON - Total Utang marang Modal|beigene.com (BGNE) - Rasio Total Utang marang Ekuitas|CKPT: Total Utang marang Modal|Rasio Total Utang marang Ekuitas elevationoncology.com|ICAD (iCAD Inc.) - Total Utang marang Modal|Total Utang marang Modal Ikena|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|viracta.com - Rasio Utang marang Ekuitas|Total Utang marang Modal MOR (MorphoSys)|NAYA - Rasio Total Utang marang Ekuitas|Ascentage Pharma Group Ltd - Total Utang marang Modal